@entity9851 was studied in 908 @entity1 with @entity943 . A proarrhythmia occurred in 29 (3.2%). When the severity of the proarrhythmia and the type of presenting @entity943 were correlated, no proarrhythmic events occurred in @entity1 who presented with benign @entity943 . Four @entity204 were attributed to the proarrhythmic effects of @entity9851 . Of these, 3 occurred in @entity1 presenting with lethal @entity943 . A total of 15 serious proarrhythmic events occurred, all of which resolved without lethal consequence. The overall proarrhythmia incidence in the lethal and potentially lethal @entity943 categories was not different (3.2 vs 3.7%, respectively). Thus, a proarrhythmia occurred in @entity1 with more advanced structural @entity299 , and occurred almost exclusively in @entity1 who presented with potentially lethal or lethal @entity943 . There was no relation between the dose of @entity9851 and the incidence of proarrhythmic events. Of the 29 proarrhythmic events, 26 occurred within 7 days (90%) of the initiation of @entity9851 therapy. Thus, @entity9851 appears to have a low proarrhythmic potential in the populations tested, including @entity1 presenting with lethal @entity943 . The implications of the @entity943 Suppression Trial on such a data base analysis are discussed.

Proarrhythmic potential of XXXX : strengths and limitations of a data base analysis.

@entity1 :: ('9606', 'Species') :: ['patients'] @entity9851 :: ('MESH:D016293', 'Chemical') :: ['Moricizine', 'moricizine'] @entity299 :: ('MESH:D006331', 'Disease') :: ['heart disease'] @entity943 :: ('MESH:D001145', 'Disease') :: ['ventricular arrhythmia', 'ventricular arrhythmias', 'Cardiac Arrhythmia'] @entity204 :: ('MESH:D003643', 'Disease') :: ['deaths']
@entity9851 :: (MESH:D016293,Chemical) :: ['moricizine']
